UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-05, Vol.22 (3), p.527-535

2019

Volltextzugriff (PDF)

Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma

Hepatology international, 2024-06, Vol.18 (3), p.973-983

2024

Volltextzugriff (PDF)

Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors

Investigational new drugs, 2014-04, Vol.32 (2), p.340-346

2014

Volltextzugriff (PDF)

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Cancer chemotherapy and pharmacology, 2014-02, Vol.73 (2), p.343-348

2014

Volltextzugriff (PDF)

Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018-05, Vol.21 (3), p.453-463

2018

Volltextzugriff (PDF)

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021, Vol.24 (1), p.156-167

2021

Volltextzugriff (PDF)

Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Targeted oncology, 2021-05, Vol.16 (3), p.401-410

2021

Volltextzugriff (PDF)

Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017-11, Vol.20 (6), p.970-977

2017

Volltextzugriff (PDF)

A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016-04, Vol.19 (2), p.586-596

2016

Volltextzugriff (PDF)

A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas

Cancer chemotherapy and pharmacology, 2013-04, Vol.71 (4), p.981-990

2013

Volltextzugriff (PDF)

Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017, Vol.20 (1), p.146-155

2017

Volltextzugriff (PDF)

Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Targeted oncology, 2021-05, Vol.16 (3), p.411-412

2021

Volltextzugriff (PDF)

Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience

Cancer chemotherapy and pharmacology, 2014-11, Vol.74 (5), p.995-1003

2014

Volltextzugriff (PDF)

Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018-09, Vol.21 (5), p.802-810

2018

Volltextzugriff (PDF)

Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB–IV gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017, Vol.20 (1), p.182-189

2017

Volltextzugriff (PDF)

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer

Cancer chemotherapy and pharmacology, 2013-11, Vol.72 (5), p.953-964

2013

Volltextzugriff (PDF)

Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement

Cancer chemotherapy and pharmacology, 2011, Vol.67 (1), p.127-136

2011

Volltextzugriff (PDF)

Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation

Cancer chemotherapy and pharmacology, 2013, Vol.71 (1), p.43-51

2013

Volltextzugriff (PDF)

Self-expandable metallic stent placement for malignant obstruction in patients with locally recurrent gastric cancer

Surgical endoscopy, 2011-05, Vol.25 (5), p.1505-1513

2011

Volltextzugriff (PDF)

Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients

Cancer chemotherapy and pharmacology, 2010-02, Vol.65 (3), p.579-587

2010

Volltextzugriff (PDF)

Clinical Outcomes and Prognostic Factors of Metastatic Gastric Carcinoma Patients Who Experience Gastrointestinal Perforation During Palliative Chemotherapy

Annals of surgical oncology, 2010-12, Vol.17 (12), p.3163-3172

2010

Volltextzugriff (PDF)

Effective diameter of balloon dilation for benign esophagojejunal anastomotic stricture after total gastrectomy

Surgical endoscopy, 2009-08, Vol.23 (8), p.1775-1780

2009

Volltextzugriff (PDF)

Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study

Cancer chemotherapy and pharmacology, 2008-07, Vol.62 (2), p.263-270

2008

Volltextzugriff (PDF)

Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular–cholangiocarcinoma

Journal of cancer research and clinical oncology, 2023-08, Vol.149 (10), p.7547-7555

2023

Volltextzugriff (PDF)

Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma

Clinical drug investigation, 2022-03, Vol.42 (3), p.283-283

2022

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

ThemaMedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma

Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)

Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis

A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival

A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas

Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer

Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience

Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11

Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB–IV gastric cancer

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer

Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement

Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation

Self-expandable metallic stent placement for malignant obstruction in patients with locally recurrent gastric cancer

Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients

Clinical Outcomes and Prognostic Factors of Metastatic Gastric Carcinoma Patients Who Experience Gastrointestinal Perforation During Palliative Chemotherapy

Effective diameter of balloon dilation for benign esophagojejunal anastomotic stricture after total gastrectomy

Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study

Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular–cholangiocarcinoma

Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma

Aktive Filter

Suchergebnisse filtern